News
Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
-
New pharmacokinetic and cardiac biomarker data further demonstrate ifetroban's potential to protect the heart and reduce cardiac damage in DMD patients NASHVILLE, Tenn. , June 23, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company committed to developing new products for rare diseases, shared the latest positive results from its Phase 2 FIGHT DMD trial evaluating ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease, at the annual Parent Project Muscular Dystrophy (PPMD) conference in Las Vegas.06/23/2025
NEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS
-
Analysis Shows 23% Reduction in Morphine Use with Favorable Safety Profile in Patients 60 Years of Age and Older NASHVILLE, Tenn. , May 27, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced the publication of its study investigating Caldolor® (intravenous ibuprofen) in older patients.05/27/2025
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions
Is Cumberland Pharmaceuticals Inc. (CPIX) a buy, sell, or hold?
Cumberland Pharmaceuticals Inc. (CPIX) can sell. Click on Rating Page for detail.
What is Cumberland Pharmaceuticals Inc.'s stock price?
The price of Cumberland Pharmaceuticals Inc. (CPIX) is 3 and it was updated on 2025-07-12 07:00:20.
Is Cumberland Pharmaceuticals Inc. (CPIX) overvalued or undervalued?
Currently Cumberland Pharmaceuticals Inc. (CPIX) is in undervalued.
News
| News |
|---|
 CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH
|
 Cumberland Pharmaceuticals, Inc. (CPIX) Q1 2025 Earnings Call Transcript
|
 Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025
|
 CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE
|
 FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference
|
Transcripts
SEC Filings
Press Releases
| StockPrice Release |
|---|
Fda approves acetadote® snda
|
Cumberland posts q1 adjusted eps of $0.01
|
More Headlines
| News |
|---|
Cumberland Pharmaceuticals Inc. (CPIX) Q4 2024 Earnings Call Transcript
|
Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth
|
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS
|
VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA
|
Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease
|
Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease
|
Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday?
|
FDA APPROVES ACETADOTE® sNDA
|
Cumberland Pharmaceuticals Inc. (CPIX) Q3 2024 Earnings Call Transcript
|
Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update
|
CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
|
New Study Compares Caldolor® (ibuprofen injection) to ketorolac
|
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS
|
Cumberland Pharmaceuticals Inc. (CPIX) Q2 2024 Earnings Call Transcript
|
Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024
|
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2024 FINANCIAL RESULTS
|
Cumberland Pharmaceuticals Inc. (CPIX) Q1 2024 Earnings Call Transcript
|
Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update
|
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS
|
NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS
|
Cumberland Pharmaceuticals Inc. (CPIX) Q4 2023 Earnings Call Transcript
|
Cumberland Pharmaceuticals Reports Annual 2023 Financial Results
|
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS
|
Cumberland Pharmaceuticals Inc. (CPIX) Q3 2023 Earnings Call Transcript
|
Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results
|
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS
|
NEW VIBATV® PEDIATRIC PUBLICATION HIGHLIGHTS ITS SAFETY IN PATIENTS 2 TO 17 YEARS OF AGE
|
Cumberland Pharmaceuticals Inc. (CPIX) Q2 2023 Earnings Call Transcript
|
Cumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023
|
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTS
|
Cumberland Pharmaceuticals Inc. (CPIX) Q1 2023 Earnings Call Transcript
|
Cumberland Pharmaceuticals Inc. (CPIX) Q4 2022 Earnings Call Transcript
|
Cumberland Pharmaceuticals, Inc. (CPIX) Q3 2022 Earnings Call Transcript
|
Cumberland Pharmaceuticals Inc. (CPIX) CEO A.J. Kazimi on Q2 2022 Results - Earnings Call Transcript
|
CUMBERLAND PHARMACEUTICALS REPORTS 2.4M PATIENT DOSES DELIVERED, NO PRODUCT RECALLS, NO FDA ISSUES IN 2021
|
Cumberland Pharmaceuticals Inc. (CPIX) CEO A.J. Kazimi on Q1 2022 Results - Earnings Call Transcript
|
Cumberland Pharmaceuticals Inc.'s (CPIX) CEO A.J. Kazimi on Q4 2021 Results - Earnings Call Transcript
|
Top Trending Penny Stocks to Buy Now? 3 to Watch
|
10 Penny Stocks To Buy In December According To Insiders
|
Cumberland Pharmaceuticals Stock (CPIX): Why The Price Surged Today
|
5 Penny Stocks To Buy In December According To Insiders
|
Penny Stocks To Buy This Week: 4 To Watch Right Now
|
List of Penny Stocks to Watch While The Stock Market is Down Today
|
OLMA Stock: The Breast Cancer Therapy News That Has Olema Pharmaceuticals Plunging Today
|
Read Why Shares Of Nano Cap Cumberland Pharma More Than Doubled
|
Cumberland Pharmaceuticals (CPIX) Stock: Why The Price Surged Today
|
Cumberland Pharmaceuticals Inc. (CPIX) CEO A.J. Kazimi on Q3 2021 Results - Earnings Call Transcript
|
Cumberland Pharmaceuticals Launches RediTrex® Product Line For Active Rheumatoid, Juvenile Idiopathic And Severe Psoriatic Arthritis
|
Cumberland Pharmaceuticals, Inc. (CPIX) CEO A.J. Kazimi on Q2 2021 Results - Earnings Call Transcript
|
Earnings Preview: Cumberland Pharmaceuticals (CPIX) Q2 Earnings Expected to Decline
|
Cumberland Pharmaceuticals Reports 2.5M Patient Doses Delivered, No Product Recalls, No FDA Issues in 2020
|
Cumberland Advisors Is 'Overweight' Health-Care: CIO
|
John Rogers' Firm Makes Changes to Portfolio in June
|
4 Small Drug Stocks Set to Escape the COVID-Led Industry Weakness
|
Vibativ® Effectively Helps Treat Secondary Bacterial Infections In COVID-19 Patients
|
Is Cumberland (CPIX) a Solid Growth Stock? 3 Reasons to Think " Yes "
|
Cumberland Pharmaceuticals Names John Hamm New Chief Financial Officer
|
Cumberland Pharmaceuticals, Inc. (CPIX) CEO A. J. Kazimi on Q1 2021 Results - Earnings Call Transcript
|
Cumberland: Q1 Earnings Insights
|
Cumberland Pharmaceuticals Reports First Quarter 2021 Financial Results & Company Update
|
Preview: Cumberland's Earnings
|
Providence's Tegria adds another company, acquires healthcare consulting firm Cumberland
|
Cumberland Pharmaceuticals, Inc. (CPIX) CEO A. J. Kazimi on Q4 2020 Results - Earnings Call Transcript
|
Cumberland Pharmaceuticals (CPIX) Beats Q4 Earnings and Revenue Estimates
|
Cumberland Pharmaceuticals Reports 9% Revenue Growth In 2020
|
Cumberland Earnings Preview
|
Where Do Hedge Funds Stand On Cumberland Pharmaceuticals, Inc. (CPIX)?
|
Introducing RediTrex®, A New Methotrexate Delivery System
|
Cumberland Pharmaceuticals, Inc. (CPIX) CEO A. J. Kazimi on Q3 2020 Results - Earnings Call Transcript
|
Recap: Cumberland Q3 Earnings
|
Cumberland's Earnings: A Preview
|
Cumberland Pharmaceuticals To Announce Third Quarter 2020 Financial Results
|
Newly Published Literature Supports Use Of Caldolor® For Postoperative Pain And Reduction Of Opioid Use
|
Cumberland Pharmaceuticals (CPIX) Q2 Earnings and Revenues Beat Estimates
|
Cumberland: Q2 Earnings Insights
|
Cumberland Pharmaceuticals Reports Second Quarter 2020 Financial Results & Company Update
|
Earnings Preview: Cumberland
|
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
|
Cumberland Pharmaceuticals To Announce Second Quarter 2020 Financial Results
|
Caldolor® Demonstrates Significant Reduction Of Opioid Use In Orthopedic Trauma Patients
|
South Jersey county again sees highest rate of coronavirus cases. See county-by-county map.
|
B.Riley FBR Keeps a Buy Rating on Intricon (IIN) - Markets
|
All You Need to Know About Cumberland (CPIX) Rating Upgrade to Buy
|
Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) Short Interest Update
|
Analysts Offer Insights on Technology Companies: Iteris (NASDAQ: ITI), Quantum (NASDAQ: QMCO) and OptimizeRx (NASDAQ: OPRX) - Markets
|
Obituary: Nancy E. Budd
|
The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic
|
Edited Transcript of CPIX earnings conference call or presentation 18-Mar-20 8:30pm GMT
|
Cumberland Pharmaceuticals: All-Time Lows Look Deserved (NASDAQ:CPIX)
|
The Daily Biotech Pulse: PhaseBio To Start Potential Pivotal COVID-19 Trial, Immunomedics CEO Quits, Tetraphase Receives Sweetened Offer
|
Is Cumberland Pharmaceuticals (CPIX) A Good Stock To Buy Now?
|
Stocks That Hit 52-Week Lows On Wednesday
|
The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas
|
33 Stocks Moving in Wednesday's Pre-Market Session
|
New Publication Reveals Real-World Usage of Vibativ® In Patients With Bacteremia Or Endocarditis
|
Is Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Excessively Paying Its CEO?
|
Cumberland Pharmaceuticals (CPIX) Q1 Earnings and Revenues Miss Estimates
|
Cumberland Q1 Adj. EPS $0.010 Misses $0.020 Estimate, Sales $9.100M Miss $9.460M Estimate
|
Cumberland Pharmaceuticals Reports First Quarter 2020 Financial Results & Company Update
|
Cumberland Pharmaceuticals, Inc. to Host Earnings Call
|
The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test
|
Cumberland Pharmaceuticals To Announce First Quarter 2020 Financial Results
|
Vibativ® Sustained Potency Confirmed In Two Surveillance Studies
|
Analysts Estimate Cumberland Pharmaceuticals (CPIX) to Report a Decline in Earnings: What to Look Out for
|
Analysts Estimate Cumberland Pharmaceuticals (CPIX) to Report a Decline in Earnings: What to Look Out for
|
NCCA officials announce further postponements to summer schedule
|
Viewray (VRAY) Receives a Hold from B.Riley FBR
|
Zacks.com featured highlights include: MagnaChip Semiconductor, PJT Partners, eXp World and Cumberland Pharmaceuticals
|
Zacks.com featured highlights include: MagnaChip Semiconductor, PJT Partners, eXp World and Cumberland Pharmaceuticals
|
4 Top-Ranked Liquid Bets to Build a Successful Portfolio
|
4 Top-Ranked Liquid Bets to Build a Successful Portfolio
|
Cumberland Pharmaceuticals Releases Inaugural Report On Its Environmental, Social And Governance (ESG) Activities
|
SCENESSE to be Prescribed in China
|
Summit Therapeutics (SMMT) Catches Eye: Stock Jumps 8.9%
|
Summit Therapeutics (SMMT) Catches Eye: Stock Jumps 8.9%
|
Ampio (AMPE) Looks Good: Stock Adds 5.2% in Session
|
Cumberland Pharma Reports Initiative To Increase Availability Of Vaprisol ?Injection For Treating Hyponatermia Associated With Critical Care Patients During Coronavirus Pandemic
|
To Help Prepare for the COVID-19 Patient Surge Cumberland Pharmaceuticals Expands Availability of Vaprisol® to Treat Hyponatremia in Critical Care Units
|
LLY, OXM, AMAG, MIST and CPIX as Zacks Bull and Bear of the Day
|
LLY, OXM, AMAG, MIST and CPIX as Zacks Bull and Bear of the Day
|
3 Drugmakers Still Worth Betting on Amid Coronavirus Woes
|
3 Drugmakers Still Worth Betting on Amid Coronavirus Woes
|
Cumberland Pharma Highlights National Initiative To Support Hospitals, Clinics Using Caldolor Injection For Treatment Of Patients With Fever, Hyperthermia, Other Symptoms Associated With Coronavirus Infection
|
Cumberland Pharmaceuticals Announces Initiative to Expand Availability of Caldolor® to Help Treat High Fevers Associated With Coronavirus Infections
|
Translate Bio (TBIO) Surges: Stock Moves 5.5% Higher
|
Translate Bio (TBIO) Surges: Stock Moves 5.5% Higher
|
Head to Head Survey: Cumberland Pharmaceuticals (NASDAQ:CPIX) vs. Merus (NASDAQ:MRUS)
|
The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test
|
The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test
|
Cumberland Pharmaceuticals Announces Initiative To Expand Availability Of VIBATIV® To Treat Hospital-Acquired & Ventilator-Associated Pneumonia Resulting From Coronavirus Infections
|
Cumberland Pharmaceuticals Announces Initiative To 'Expand Availability' Of VIBATIV To Treat ospital-Acquired & Ventilator-ASsociated Pneumonia
|
Tracking John Rogers' Ariel Investments Portfolio - Q4 2019 Update
|
Cumberland Pharmaceuticals Reports 17% Revenue Growth For The Full Year 2019
|
Earnings Scheduled For March 18, 2020
|
The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
|
Cumberland Q4 Adj. EPS $0.09 Beats $0.01 Estimate, Sales $13.7M Beat $11.34M Estimate
|
Caldolor® Demonstrates Favorable Safety Profile In Newborns
|
The Week Ahead In Biotech: COVID-19 Updates, Tapering Earnings Flow, Eton's Seizure Drug Review
|
The Week Ahead In Biotech: COVID-19 Updates, Tapering Earnings Flow, Eton's Seizure Drug Review
|
The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment
|
Earnings Preview: Cumberland Pharmaceuticals (CPIX) Q4 Earnings Expected to Decline
|
The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
|
The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
|
Cumberland Pharmaceuticals Reschedules Fourth Quarter And Annual 2019 Financial Results
|
Cumberland Pharmaceuticals Reschedules Fourth Quarter And Annual 2019 Financial Results To Wed. Mar. 18 After The Close
|
Cumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2019 Financial Results
|
The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO
|
Stocks That Hit 52-Week Lows On Friday
|
The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy
|
Analysts' Top Conglomerates Picks: Intricon (IIN), Aspen Aerogels (ASPN)
|
Edited Transcript of TBPH earnings conference call or presentation 24-Feb-20 10:00pm GMT
|
Viewray (VRAY) Receives a Hold from B.Riley FBR
|
Viewray (VRAY) Receives a Hold from B.Riley FBR
|
3 “Strong Buy” Biotech Stocks That Can Inject a Healthy Dose of Upside
|
Will Theravance Biopharma Finally Break Out in 2020?
|
Cumberland Pharmaceuticals Announces The National Launch Of A New Caldolor Ready-To-Use Product
|
Cumberland Pharmaceuticals Announces The National Launch Of A New Caldolor Ready-To-Use Product
|
Edited Transcript of CPIX earnings conference call or presentation 12-Nov-19 9:30pm GMT
|
Cumberland Pharmaceuticals To Hold Update Call To Discuss Recent Major Developments
|
Cumberland Pharmaceuticals, Inc. (CPIX): Hedge Funds In Wait-and-See Mode
|
New Strong Sell Stocks for December 4th
|
B. Riley Maintains Buy on Cumberland, Raises Price Target to $9.75
|
Cumberland Pharma Recieves FDA Approval of its RediTrex
|
Staffordshire and Cheshire's first-class opponents for 2020 are announced
|
The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate
|
Stocks That Hit 52-Week Lows On Thursday
|
The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout
|
B. Riley FBR Maintains Buy on Cumberland, Lowers Price Target to $9
|
Cumberland Q3 EPS $(0.13) Misses $0.11 Estimate, Sales $10.4M Miss $12.65M Estimate
|
Cumberland Pharmaceuticals (CPIX) Dips More Than Broader Markets: What You Should Know
|
Cumberland Pharmaceuticals (CPIX) Stock Sinks As Market Gains: What You Should Know
|
Cumberland Pharmaceuticals (CPIX) Outpaces Stock Market Gains: What You Should Know
|
Cumberland Pharmaceuticals (CPIX) Stock Sinks As Market Gains: What You Should Know
|
UPDATE: Cumberland Awarded $1M+ In Funding From FDA Through Orphan Drug Grant Program
|
Cumberland Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
|
Cumberland (CPIX) Upgraded to Strong Buy: What Does It Mean for the Stock?
|
UPDATE: Cumberland Says FDA 'recommended splitting up the submission into several separate submissions, each containing a single proposed labeling claim or group of related labeling claims, with additional data...'
|
Here is Why Growth Investors Should Buy Cumberland (CPIX) Now
|
New Strong Buy Stocks for September 5th
|
Stocks That Hit 52-Week Lows On Wednesday
|
The Daily Biotech Pulse: EC Approves Roche's Tecentriq For Breast Cancer, Trevena On Track For NDA Resubmission, Edap Earnings
|
Cumberland Q2 EPS $0.1 Beats $0.07 Estimate, Sales $11.581M Miss $12.59M Estimate
|
Cumberland Pharmaceuticals (CPIX) Earnings Expected to Grow: What to Know Ahead of Q2 Release
|
Acer Shares Down on FDA's CRL for Genetic Disorder Treatment
|
Cumberland Pharmaceuticals (CPIX) Gains As Market Dips: What You Should Know
|
Cumberland Pharma Signs Exclusive License Deal For Distribution In China
|
Cumberland Pharmaceuticals Says Has Reached Agreement With Hong Kong WinHealth Pharmaceuticals
|
30 Stocks Moving In Monday's Mid-Day Session
|
Cumberland Pharma Reports Strategic Review
|
Cumberland Q4 EPS $0.10 Beats $(0.16) Estimate, Sales $13.5M Beat $10.98M Estimate
|
Cumberland Pharma 8-K Shows Co. Received Notice Of Approval From FDA For Application Related To Next-Gen Caldolor
|
Cumberland Pharmaceuticals Receives FDA Notification Setting Sept 2019 As PDUFA Action Date For Approval Decision Regarding NDA For Methotrexate Product Line; Remitted Payment Of $1.3M To FDA For PDUFA Application Fee Associated With Methotrexate
|
Cumberland Pharmaceuticals Says On Jan 4 FDA Accepted For Review NDA For Approval Of Methotrexate Product Line; Projected PDUFA Date for November 2018
|
Cumberland Pharmaceuticals Inc. Q3 EPS $(0.05) Down From $0.01 YoY, Sales $8.493M Miss $9.16M Estimate
|
Cumberland Pharma To Purchase VIBATIV From Theravance Biopharma For $20M Plus $5M In Added Payment In Early 2019, Tiered Royalties Of Up To 20% On Future US Net Product Sales
|
Stocks Which Set New 52-Week Low Yesterday, October 23rd
|
Cumberland Pharmaceuticals Submitted An Amendment To Application For Approval Of Caldolor (ibuprofen) Injection Product And Will Await FDA's Response Decision; NOTE: Co. On Aug. 2 Received CRL Outlining Additional Information Needed For Caldolor Approval
|
Cumberland Pharma Reports Study Results Published In 'Lung Cancer: Targets And Therapy' Showed 'subcutaneous amifostine administered before radiotherapy postponed the onset of acute esophagitis in stage 3 small cell lung cancer patients...'
|
Cumberland Q2 Adj. EPS $0.01 Beats $(0.08) Estimate, Sales $10.164M Beat $9.94M Estimate
|
Stocks Which Set New 52-Week Low Yesterday, August 7th
|
Cumberland Q1 EPS $(0.15) Misses $(0.02) Estimate, Sales $8.58M Miss $9.71M Estimate
|
B. Riley Initiates Coverage On Cumberland with Buy Rating, Announces $9.25 Price Target
|
Cumberland Pharmaceuticals Reports Newly Published Data Demonstrates Amifostine Reduces Gastro-Intestinal Toxicity For Multiple Myeloma Patients
|
Cumberland Pharma Reports Q3 EPS $(0.05) vs. $0.01 In Same Qtr. Last Year, Sales $11.2M vs. $8.8M YoY
|
Cumberland Pharma Reports Q2 Adj. Loss/Share $(0.05) vs. $0.04 EPS In Same Qtr. Last Year, Sales $8.7M vs. $7.4M YoY
|
Cumberland Pharmaceuticals Initiates U.S. Shipments Of Dexrazoxane For Oncology Patient Support
|
Cumberland Pharmaceuticals Reports Q1 Adj. EPS $(0.02), Flat vs Same Qtr. Last Year, Sales $9.6M vs $7.7M YoY
|
Cumberland Pharma to Partner with Poly Pharma for Kristalose in the US
|
Cumberland Pharma Reports Publication Of A Trial Providing Evidence Its Caldolor Improves Postoperative Pain, Decreases Opioid Use
|
Cumberland Pharma Reports Q4 EPS $(0.05) vs $0.01 in Same Qtr. Last Year, Sales $9.081M vs $8.037M YoY
|
U.S. Court Of Appeals Affirms Cumberland Pharmaceuticals' Victory In Patent Litigation Case For Acetadote Product
|
U.S. Appeals Court Rules In Favor of Cumberland Pharmaceuticals Over Mylan In Patent Dispute Realted To Acetadote
|
Cumberland Pharma and Clinigen Enter Exclusive US Commercialization Agreement for Totect
|
Cumberland Pharmaceuticals Acquires U.S. Rights to Nordic Group's Methotrexate Injection Products, Terms Not Disclosed
|
Cumberland Pharmaceuticals Reports Q3 Adj EPS $0.06, Revenues $8.8M
|
Cumberland Pharmaceuticals Launches Promotion Of Ethyol In The United States For Oncology Patient Support
|
Cumberland Pharmaceuticals Announces New Program To Develop Portaban For Portal Hypertension, FDA Clears Investigational New Drug Submission
|
Cumberland Pharma Reports Commencement of US Shipments of Ethyol for Oncology Patient Support
|
Cumberland Pharmaceuticals Reports Q2 EPS $0.04 vs. Prior Year Quarter $0.09, Rev. $7.4M vs. Prior Year Quarter $8.9M
|
Cumberland Pharmaceuticals Reports Q1 EPS $(0.02) vs. Prior Year Quarter $0.00, Rev. $7.737M vs. Prior Year Quarter $8.68M
|
Cumberland Pharmaceuticals Reports New Program To Develop Vasculan For Systemic Sclerosis, FDA Clears IND Submission and Phase II Study Initiated
|
Cumberland Pharma Reports Launch of Caldolor for Treatment of Pain, Fever in Children
|
Cumberland Pharmaceuticals Reports Q4 EPS $0.03 vs. Prior Year Quarter $0.10, REv. $8M vs. Prior Year Quarter $9.3M
|
Caldolor Approved For Use In Pediatric Patients
|
Cumberland Pharmaceuticals Announces Favorable Acetadote Patent Ruling
|
Cumberland Pharma Reports Q3 EPS $0.01, Sales $7.89M, no estimates
|
U.S. District Court Rules in Favor of Cumberland Pharmaceuticals in Lawsuit vs Mylan for Infringement of Co's 445 Acetadote Patent -8-K
|
Cumberland Pharma Reports Strategic Alliance with Clinigen Group to 'Maximize Commercial Potential of Future Products'
|
Cumberland Pharmaceuticals Reports Q2 EPS $0.09, Estimates Not Available
|
Top 4 NASDAQ Stocks In The Drug Manufacturers-Other Industry With The Highest EPS Growth Forecast For Next 5 Years
|
Cumberland Pharma Reports Q1 Adj. EPS $0.09, Sales $8.7M
|
Cumberland Pharma Reports Q4 Adj. EPS $0.10
|
Cumberland Pharmaceuticals Announces Pipeline Expansion With Boxaban
|
Cumberland Reports Phase IV Studies Published Supporting Safety of Shortened Infusion Time of Caldolor Injection
|
Cumberland Pharmaceuticals Inc. Reports Q3 EPS of $0.04, Down 20% YOY; Revenue of $9.70M, Down 5% YOY
|
Cumberland Pharmaceuticals Inc. Reports Q1 EPS of $0.02, Down 60% YOY; Revenue of $8.09M, Down 21% YOY
|
Cumberland Announces Vaprisol Promotion
|
Cumberland Pharmaceuticals: Caldolor Study Met Primary Endpoint
|
Cumberland Pharmaceuticals Inc. Reports Q4 EPS of $(0.08) vs $0.05 Est; Revenue of $8.16M vs $8.19M Est
|
Cumberland Pharmaceuticals Acquires Vaprisol® from Astellas Pharma US; Terms Undisclosed
|
Cumberland Pharmaceuticals Inc. Reports Q3 EPS of $(0.04) vs $0.00 Est; Revenue of $6.53M vs $7.60M Est
|
Top 4 Small-Cap Stocks In The Drug Manufacturers-Other Industry With The Lowest PEG Ratio
|
Cumberland Pharmaceuticals Inc. Reports Q2 EPS of $(0.03) Which May Not Compare $0.02 Est; Revenue of $7.08M Which May Not Compare $9.40M Est
|
Top 4 Small-Cap Stocks In The Drug Manufacturers-Other Industry With The Lowest PEG Ratio
|
Cumberland Pharmaceuticals Inc. Reports Q1 EPS of $0.05, Inline; Revenue of $10.30M vs $10.0M Est
|
UBS Maintains Neutral on Cumberland Pharmaceuticals Inc., Raises PT to $5.50
|
CPIX Ratings Summary
CPIX Quant Ranking
